ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

ALS Investment Fund Is Launched

by Lisa M. Jarvis
May 5, 2014 | APPEARED IN VOLUME 92, ISSUE 18

Three European entrepreneurs, all recently diagnosed with the rare and fatal neurodegenerative disease amyotrophic lateral sclerosis (ALS), have launched an investment fund to find a cure for their disease. The group has already initiated the world’s largest genetic research study related to the disease and now has turned its attention to translating disparate academic research into treatments. The entrepreneurs’ goal is to raise $140 million from “impact investors”—investors interested in social benefit alongside a financial return. The founders say the fund is the first to specifically target a rare disease.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment